Status:

UNKNOWN

NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC

Lead Sponsor:

National Taiwan University Hospital

Conditions:

HBV/HCV Co-infection

Eligibility:

All Genders

20-70 years

Phase:

NA

Brief Summary

HBV reactivation is common in HCV/HBV coinfected patients receiving DAA therapy for chronic hepatitis C. How to prevent HBV reactivation remains unclear. In this trial, we aim to investigate whether p...

Detailed Description

We will determine the incidence of virologic and clinical reactivation of HBV during DAA treatment for CHC, in two prophylactic groups versus control group. We will also examine whether extending the ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Age ≥20 years;
  • Anti-HCV positive and HCV RNA \>1000 IU/ml;
  • Any HCV genotype; all received 12 weeks of DAA treatment.
  • Treatment naïve or experienced of pegylated interferon/ribavirin;
  • Concurrent HBV infection which is defined by positive HBsAg for at least 6 months.
  • Exclusion criteria
  • History of treatment regimen that included any kind of direct antiviral agents;
  • Presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc;
  • Uncontrolled diabetes mellitus (Hba1c \>8.5);
  • Current evidence or suspicion of malignancy;
  • Severe cardiovascular or other severe comorbid diseases;
  • Autoimmune disorders;
  • Presence of liver cirrhosis clinically or pathologically;
  • Any one of following hematology or biochemical or clinical abnormalities:
  • AST/ALT \>10x ULN, Albumin \<3.5g/dL, Bilirubin \>2.5mg/dL, eGFR \<30 ml/min/1.73m2, prothrombin time prolongation \>4 sec or INR \>1.7, platelet count \<100 x 103 uL, and history or presence of ascites or hepatic encephalopathy.
  • Child-bearing age women without the willing to contraceptive control; pregnant women or lactating women.

Exclusion

    Key Trial Info

    Start Date :

    August 1 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 28 2020

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT04405011

    Start Date

    August 1 2018

    End Date

    December 28 2020

    Last Update

    July 2 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    National Taiwan University Hospital

    Taipei, Taiwan, 100

    2

    TC Chen

    Taipei, Taiwan, 100